Revenue Expected to Exceed $18 Million for 2012 Fourth Quarter
Revenue Growth Driven by Direct Sales to End-Users in North America
IRVINE, CA -- (Marketwire) -- 01/07/13 -- BIOLASE, Inc. (NASDAQ:
BIOL), the world's leading dental laser manufacturer and distributor,
announced today that, based on a preliminary review of its financial
performance for the fourth quarter ended December 31, 2012, the
Company expects to exceed its previous guidance and report net
revenue in excess of $18 million.
Federico Pignatelli, Chairman and CEO of BIOLASE, said, "We are very
pleased with the strong growth in our core dental laser products and
the trends that are accelerating with the adoption of our
WaterLase(R) technology and diode laser systems. Our strong revenue
growth in the 2012 fourth quarter compared to the prior year period
was primarily due to the increased demand for our flagship WaterLase
iPlus(TM) and our new EPIC 10(TM) soft tissue diode laser. Revenues
were also bolstered by sales of our mid-priced WaterLase products and
our digital imaging products, including the initial sales of our
"After closing 2012 on a strong note, we are very excited to look
ahead to 2013 and beyond as we expect a substantial acceleration in
the adoption of lasers, specifically our core WaterLase technology,
in dental practices around the world over the next three to five
years. We are very confident that all-tissue lasers will become the
standard of care in dental practices worldwide. Furthermore, as we
move forward in 2013 we do not expect to be troubled with the
multitude of extraneous issues that we faced throughout our
challenging turnaround, including exiting our exclusive global
distribution relationship with Henry Schein, Inc. (NASDAQ: HSIC), and
moving to a direct sales model in North America and multi-distributor
model internationally," concluded Pignatelli.
BIOLASE's patented WaterLase technology combines its
proprietary 2,780nm YSGG laser energy, air, and water that all
emanate from its patented hand piece to symbiotically excite water
molecules from within both the spray and the target tissue. This
results in a biological ablation of both hard- and soft-tissue.
Currently, BIOLASE offers several variations of WaterLase laser
systems, including the flagship iPlus, the mid-priced MDX(TM) 450 and
300, and certified pre-owned MD Turbos(TM).
About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that
develops, manufactures and markets dental lasers and also distributes
and markets dental imaging equipment; products that are focused on
technologies that advance the practice of dentistry and medicine. The
Company's laser products incorporate approximately 290 patented and
patent-pending technologies designed to provide biological treatment
and clinically superior performance with less pain and faster
recovery times. Its imaging products provide cutting-edge technology
at competitive prices to deliver the best results for dentists and
patients. BIOLASE's principal products are dental laser systems that
perform a broad range of dental procedures, including cosmetic and
complex surgical applications, and a full line of dental imaging
equipment and CAD/CAM systems. BIOLASE has sold more than 21,000
lasers. Other products under development address ophthalmology and
other medical and consumer markets.
For updates and information on WaterLase and laser dentistry, find
BIOLASE online at www.biolase.com, Facebook at
www.facebook.com/biolaseinc, Twitter at twitter.com/biolaseinc, and
YouTube at www.youtube.com/biolasevideos.
For further information, please contact:
In-Site Communications, Inc.
Press spacebar to pause and continue. Press esc to stop.